Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management
Open Access
- 17 November 2016
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 9 (3), 189-199
- https://doi.org/10.1177/1758834016678149
Abstract
Neuroendocrine tumors (NETs) are rare neoplasms that can arise from any tissue. They are classified based on embryonic gut derivative (i.e. foregut, midgut and hindgut) with midgut tumors being the most common (e.g. gastrointestinal NET). The second most common category of NETs is that which arises from the lung. In fact, 25% of primary lung cancers are NETs, including small cell lung cancer (SCLC), which comprises 20% of all lung cancers. The remaining 5% are large cell neuroendocrine cancer (LCNEC, 3%), typical carcinoids (TCs, 1.8%), and atypical carcinoids (ACs, 0.2%). The less common TCs/ACs are well differentiated lung NETs. Their incidence has been increasing in more recent years and although these tumors are slow growing, advanced disease is associated with poor survival. There have been advances in classification of lung NETs that have allowed for more appropriate management upfront. They are cured by surgical resection when disease is limited. However, advanced and metastatic disease requires medical therapy that is ever changing and expanding. In this review, the aim is to summarize the current understanding and classification of well differentiated lung NETs (i.e. TCs and ACs), and focus on recent updates in medical management of advanced disease, along with a brief discussion on potential future discoveries.This publication has 67 references indexed in Scilit:
- Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumorsLaboratory Investigation, 2012
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- DAXX / ATRX , MEN1 , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine TumorsScience, 2011
- Long-term survival after surgical management of neuroendocrine hepatic metastasesHPB, 2010
- NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine TumorsPancreas, 2010
- Molecular genetics of gastroenteropancreatic neuroendocrine tumorsCurrent Opinion in Oncology, 2009
- Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: A baseline and 2-year repeat studyLung Cancer, 2008
- Prediction and Diagnosis of Bone Metastases in Well-Differentiated Gastro-Entero-Pancreatic Endocrine Cancer: A Prospective Comparison of Whole Body Magnetic Resonance Imaging and Somatostatin Receptor ScintigraphyJournal of Clinical Endocrinology & Metabolism, 2008
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- Octreoscan in patients with bronchial carcinoid tumoursClinical Endocrinology, 2003